Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Making informed decisions and managing regret after prostate cancer treatment

2.

Analysis of 2021 data shows new cancer diagnoses did not rebound as expected following pandemic

3.

Chemicals in Sewage Sludge Fertilizer Pose Cancer Risk, EPA Says

4.

Hypnotherapy may offer real benefits for cancer patient care

5.

Study Finds Actionable Mutations in Brain Mets of Breast Cancer Patients


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot